Price
Target price
€20.20
€20.20
-0.980%
-0.2
-0.980%
€57.43
29.01.26 / Stuttgart Stock Exchange
WKN: A1XCY0 / Symbol: RARE / Name: Ultragenyx / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Ultragenyx Pharmaceutical Inc. Stock
Ultragenyx Pharmaceutical Inc. shows a slight decrease today, losing -€0.200 (-0.980%) compared to yesterday.
The stock is an absolute favorite of our community with 25 Buy predictions and no Sell predictions.
Based on the current price of 20.2 € the target price of 57 € shows a potential of 182.18% for Ultragenyx Pharmaceutical Inc. which would more than double the current price.
Pros and Cons of Ultragenyx Pharmaceutical Inc. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
?
M***** P*******
Cons
?
G***** c******* t* c**********
?
S********** s********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Ultragenyx Pharmaceutical Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. | -0.980% | 2.538% | -29.861% | -50.246% | 20.238% | -50.246% | -82.435% |
| Ironwood Pharmaceuticals | -2.010% | -14.097% | 46.617% | 10.795% | 46.617% | -62.772% | -54.651% |
| Novocure Ltd | -0.090% | -14.481% | -8.296% | -57.902% | -8.822% | -87.638% | -92.209% |
| Iovance Biotherapeutics Inc. | -2.560% | -4.359% | -7.602% | -62.406% | -7.504% | -70.770% | -93.923% |
Comments
Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price target lowered by analysts at HC Wainwright from $80.00 to $60.00. They now have a "buy" rating on the stock.
Show more
Ratings data for RARE provided by MarketBeat
Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price target lowered by analysts at Guggenheim from $64.00 to $52.00. They now have a "buy" rating on the stock.
Show more
Ratings data for RARE provided by MarketBeat
Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price target lowered by analysts at Bank of America Corporation from $72.00 to $58.00. They now have a "buy" rating on the stock.
Show more
Ratings data for RARE provided by MarketBeat
News
Why Ultragenyx Pharmaceutical Stock Is Bouncing Back Today
While Ultragenyx Pharmaceutical (NASDAQ: RARE) provided the market with disappointing news yesterday -- shares plunged more than 42% -- it appears that investors aren't completely writing off the
Why Ultragenyx Pharmaceuticals Stock Is Plummeting Today
Heading into 2026 on an inauspicious note, Ultragenyx Pharmaceuticals (NASDAQ: RARE), a pharmaceutical company specializing in treatments for rare and ultra-rare genetic diseases, announced
Ultragenyx (RARE) Q2 Revenue Up 13%
Ultragenyx Pharmaceutical (NASDAQ:RARE), a rare disease drug developer, reported its second quarter 2025 earnings on August 5, 2025. Both revenue and earnings per share exceeded Wall Street